Actually Obleix is right n = 10 is quite low (although fine for rare diseases). Even though it says statistically significant we will need to get way more data on who the patients where (m/f, age, progression of disease, amt of ARB, blood-drug levels etc.) before we can break out the champagne. Secondly, only seven of those qualified for final analysis.
It does help to say that with a small study, we will need more info as investors/doctors/patients/mgmt before we are confident of us shareholders getting some big pay days. De-risking this will include some form of licensing deal I would imagine.
That is why a Ph3 is needed next with a much larger pop. Else on just the Ph2 we could go straight to commercialization.
As a holder I am happy for the company and everyone involved. As an investor, I await more info and a ph3.
- Forums
- ASX - By Stock
- Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
Actually Obleix is right n = 10 is quite low (although fine for...
-
- There are more pages in this discussion • 228 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
43.0¢ |
Change
-0.020(4.44%) |
Mkt cap ! $247.7M |
Open | High | Low | Value | Volume |
43.5¢ | 43.8¢ | 42.0¢ | $318.8K | 741.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 137256 | 42.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.0¢ | 113925 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 137256 | 0.425 |
10 | 204760 | 0.420 |
12 | 259386 | 0.415 |
13 | 219209 | 0.410 |
11 | 159722 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.430 | 113925 | 8 |
0.435 | 32308 | 5 |
0.440 | 55392 | 6 |
0.445 | 13147 | 2 |
0.450 | 85306 | 7 |
Last trade - 10.29am 04/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |